


5th JOINT MEETING BELGIAN-DUTCH NEUROMUSCULAR STUDY GROUP AND GERMAN REFERENCE CENTER FOR NEUROMUSCULAR DISEASES, DGNN

19-20 APRIL, 2024

HOTEL KASTEEL BLOEMENDAL
VAALS, THE NETHERLANDS



PROGRAM Friday 19 April 2024

08:30 - 09:00 Registration (coffee/tea)

09:00 - 09:10 Welcome (J. Weis, K. Claeys)

09:10 - 10:36 **SESSION 1: Motor neuron diseases**

Chairpersons: Bjarne Udd, Michael Van Es

Therapeutic (r)evolution in SMA: where are we now and what about the future? - *Liesbeth De Waele (Belgium)*

Novel developments in ALS - *Michael Van Es (The Netherlands)*

Oral presentations from abstracts

Bi-allelic ATXN2 repeat expansions cause autosomal, recessive ALS - *Koen Demaegd*

The German MND-Net Tissue Bank - an update - *Joachim Weis*

Risdiplam treatment in adult patients with spinal muscular atrophy: a prospective study investigating clinical, functional, and patient-reported outcome measures over 12 months

- *Louise Iferbeke*

10:36 - 11:00 **Coffee break**

11:00 - 12:13 **SESSION 2: Neuromuscular junction disorders**

Chairpersons: Marc De Baets, Mario Losen

Update on Myasthenia gravis – optimizing treatment for all patients - *Martijn Tannemaat (The Netherlands)*

Oral presentations from abstracts

Congenital myasthenic syndromes in Belgium: genetic and clinical characterization of pediatric and adult patients - *Nathalie Smeets*

The relevance of complement activation in myasthenia gravis – a quantification study using the experimental passive transfer MG model - *Anja Schöttler*

Hock immunization, an update of the experimental autoimmune myasthenia gravis (EAMG) mouse model - *Marina Mané Damas*

Are thymus-resident plasma cells prognostic factors of thymectomy in patients with anti-acetylcholine receptor myasthenia gravis? - *Britt Arets*

12:13 - 13:00 A tribute to Prof. J. Michael Schröder, 1937-2023 (*Joachim Weis, Stephan Züchner, Claudia Sommer, Vincent Timmerman, Hans-Hilmar Goebel*)

13:00 - 14:00 **Lunch**

14:00 - 16:39 **SESSION 3: Peripheral neuropathies I**

Chairpersons: Claudia Sommer, Peter Van den Bergh

New EAN/PNS GBS guideline - *Pieter Van Doorn (The Netherlands)*

Pathophysiology of demyelinating neuropathies - *Ruth Stassart (Germany)*

Genomics-To-Therapy: a concept illustrated by CMT-SORD - *Stephan Züchner (USA)*

Oral presentations from abstracts

Supervised machine learning algorithms for diagnosing chronic inflammatory demyelinating polyradiculoneuropathy - *Iris van Doorn*
Loss-of-function mutations in the nuclear envelope gene FAM169A cause autosomal dominant lower and upper motor neuropathy - *Maike Dohrn*
Recurrent missense variant in ITPR3 causes demyelinating Charcot-Marie-Tooth neuropathy with remarkably variable severity - *Daniqie Beijer*
Frequency and clinical characterization of SORD-Related neuropathy in a Belgian cohort - *Matthias Opsomer*
Dominant OGDH mutations cause peripheral neuropathy with ataxia and optical atrophy - *Liedewei Van de Vondel*
Let's drop some Fats: The idiosyncrasies of lipid droplets in iPSC-Schwann cell precursor cells from Charcot-Marie-Tooth disease type 1A patients. - *Koen Kuipers*
Inducible dental pulp stem cells-derived Schwann cells for CMT1A modelling - *Nathalie Dirkx*

16:39 - 17:00 **Coffee break**

17:00 - 19:14 **SESSION 4: Peripheral neuropathies II**

Chairpersons: Martin Lammens, Stephan Goedee
Novel therapeutic avenues in hereditary peripheral neuropathies - *Davide Pareyson (Italy)*
Proteostasis regulators in neuromuscular diseases – learning from zebrafish models - *Juliane Bremer (Germany)*

Oral presentations from abstracts

Comparison of efficacy outcomes with Vutrisiran vs. Patisiran in hATTR amyloidosis with polyneuropathy: post-hoc analysis of the HELIOS-A study - *Valérie Dupong*
A comparison of neurofilament in serum, cerebrospinal fluid and peripheral nerve in patients undergoing nerve biopsy - *Simon Streit*
Autophagy phenotypical screening identified new molecules to restore neuronal proteostasis in cellular models of HSPB1 and HSPB8-associated peripheral neuropathies - *Angela Sisto*
The effects of PMP22 overexpression on cellular stress in Charcot-Marie-Tooth disease type 1A - *Hanne Jeurissen*
PDE4D inhibition with Gebr32a stimulates Schwann cell differentiation and improves the functional outcome in models for Charcot Marie Tooth disease 1A - *Tim Vanganswinkel*
Foreign body response hampers tissue integration of a poly(ϵ -caprolactone) nanofibre-containing scaffold for peripheral nerve repair - *Pascal Achenbach*
Nerve transfers in children with Arthrogryposis Multiplex Congenita - *Benedikt Schäfer*

19:30 **Dinner**

PROGRAM Saturday 20 April 2024

08:30 - 10:33 **SESSION 5: Muscle disorders I**

Chairpersons: Werner Stenzel, Anne Schänzer
Neuromuscular imaging: a better eye on nerves and muscles - *Nens van Alfen (The Netherlands)*
Clinical and imaging advances in inflammatory myopathies - *Anneke van der Kooi (The Netherlands)*
Whats New in Pathogenesis of IIM - *Werner Stenzel (Germany)*

Oral presentations from abstracts

The adiponectin receptor agonist, ALY688: a promising therapeutic for fibrosis in the dystrophic muscle - *Nicolas Dubuisson*
Inhibition of KDM5A reverses pathological features in sporadic inclusion body myositis-like cell models - *Geert de Vries*
Automated morphometric analysis of ICAM-1 expression highlights similarities and differences between myositis subtypes - *Anne Schänzer*

10:33 - 11:00 **Coffee break**

11:00 - 13:05 **SESSION 6: Muscle disorders II**

Chairpersons: Ingo Kurth, Anneke Van der Kooi
Genetics in distal muscle diseases - *Bjarne Udd (Finland)*
Advances and caveats of novel therapies in (neuro)muscular disorders - *Benedikt Schoser (Germany)*

Oral presentations from abstracts

Comprehensive four-year disease progression assessment of DM1, based on the Dutch MYODRAFT registry - *Leandre la Fontaine*
Life expectancy and causes of death in patients with Myotonic Dystrophy type 2. - *Alide Tieleman*
Heterozygous SPTAN1 loss-of-function variants cause early childhood onset distal myopathy - *Jonathan De Winter*
The exception that proves the rule: a titin truncating variant causing a dominant myopathy with cardiac involvement - *Kristl Claeys*
Alpha-synuclein as potential biomarker in Inclusion body myositis – a histological and serological study - *Alexander Mensch*

13:05 - 13:10 **Closure** (J. Weis, K. Claeys)

13:10 **Lunch**

